TY  - JOUR

T1  - Dupilumab safety and efficacy in a phase III open-label extension trial in children 6–11 years of age with severe atopic dermatitis

JO  - Dermatology and Therapy

UR  - https://eprints.whiterose.ac.uk/id/eprint/204730

PY  - 2023/09/26

AU  - Cork MJ

AU  - Thaçi D

AU  - Eichenfield LF

AU  - Arkwright PD

AU  - Chen Z

AU  - Thomas RB

AU  - Kosloski MP

AU  - Dubost-Brama A

AU  - Prescilla R

AU  - Bansal A

AU  - Levit NA

ED  - 

DO  - DOI: 10.1007/s13555-023-01016-9

PB  - Springer Science and Business Media LLC

VL  - 13

SP  - 2697

EP  - 2719

Y2  - 2024/12/22

ER  -